Trial reportInflammopharmacology2017
Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
Trial report in Inflammopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.Chinese journal of integrative medicine · 2025Review
- A Perspective on the Interaction Between Recurrent Lower Urinary Tract Infections and Irritable Bowel Syndrome.Nutrients · 2024Article
- The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis.Translational andrology and urology · 2022Article
- The effect of Qianliekang tablets on the clinical efficacy, immune function, and inflammatory factor levels in the prostatic fluid of elderly chronic prostatitis patients.American journal of translational research · 2021Article
- The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis.Central European journal of urology · 2021Article
- Effect of tamsulosin on testis histopathology and serum hormones in adult rats: Experimental study.International journal of reproductive biomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInflammation and Cyclooxygenase-2 (COX-2) as a part of it are common in BPH specimens and may play a role in the pathogenesis of the disease through cytokines that promote cell growth or lead to smooth muscle contraction. The aim of this study is to analyze whether combination therapy with omega-3 fatty acids, which have anti-inflammatory and COX-2 inhibitory effects, and tamsulocin plus finasteride offers an advantage compared to tamsulocin plus finasteride therapy in patients with BPH. MATERIALS AND
methodsThis is a single-center blinded clinical trial. One hundred consecutive men between 50 and 70 years of age and no other comorbidities with LUTS and BPH were entered into the study and were randomized to receive omega-3 fatty acids 300 mg three times a day with meals plus tamsulocin 0.4 mg at bed time and finasteride 5 mg/day (study group) versus tamsulocin 0.4 mg at bed time and finasteride 5 mg/day (control group) for 6 months. The efficacy and safety of treatments were assessed at baseline and at month one, three and six.
resultsIn our population, both treatments (groups study and control) produced statistically significant improvements in IPSS, Q
conclusionIt can be concluded that association of omega-3 fatty acids with tamsulocin and finasteride may produce better clinical results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.